HIV/HBV co-infection linked to worse immune recovery and death, but tenofovir improves outcomes
Multiple social and health factors associated with irregular attendance at London HIV clinics
Primary care doctors and nurse practitioners can successfully treat people with hepatitis C
VRC01 antibody delays but does not prevent HIV rebound after antiretroviral treatment interruption
More people with HIV are achieving viral suppression in US, but about 40% remain above transmission thresholds
Long-acting oral antiretroviral MK-8591 could represent 'paradigm shift' in HIV treatment and prophylaxis
Antidepressant modestly improves HIV-related cognitive impairment
Tailored programmes encourage black gay men to start and stay on PrEP in US study
Combination inhibitor BMS-986197 demonstrates good activity against HIV in early study
High sexually transmitted infection rates among men on PrEP supports more frequent monitoring
HIV-related factors increase risk of stroke
Sofosbuvir/velpatasvir for hepatitis C can be administered with most antiretrovirals
Transgender people are at high risk for HIV, but too little is known about prevention and treatment for this population
Rapid rise in PrEP awareness in US gay men, but only 5% have used PrEP
Indiana HIV epidemic among people who inject drugs is controlled, but ongoing vigilance is needed
Ravidasvir plus sofosbuvir demonstrates high cure rate for people with hepatitis C genotype 4
START study shows that people starting HIV treatment earlier have better quality of life
South Africa’s XDR-TB epidemic is due to transmission rather than evolution of resistant strains
